Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tremelimumab - AstraZeneca

Next Previous
X
Search
Drug Profile

Tremelimumab - AstraZeneca

Alternative Names: Anti CTLA 4 monoclonal antibody - AstraZeneca; CP-675; CP-675,206; IMJUDO; Ticilimumab

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AstraZeneca; Cancer Research Institute; Dana-Farber Cancer Institute; MedImmune; Pfizer; University of Alabama at Birmingham
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Non-small cell lung cancer
  • Phase III Bladder cancer; Head and neck cancer; Malignant-mesothelioma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase II Biliary cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Germ cell cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer
  • Phase I/II Haematological malignancies
  • No development reported Vulvovaginal cancer
  • Discontinued Diffuse large B cell lymphoma; Gynaecological cancer; Malignant melanoma; Myelodysplastic syndromes

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Neoadjuvant therapy) in USA (IV, Infusion)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Vulvovaginal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
  • 05 Sep 2024 AstraZeneca announces intention to submit regulatory application for Small cell lung cancer (First-line therapy, Combination therapy) in the second half of 2024 (AstraZeneca pipeline, September 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top